Novartis Pharmaceuticals Australia Pty Ltd—Lumiracoxib (Prexige)

What are the defects?

The Therapeutic Goods Administration has cancelled the registration of Lumiracoxib because of serious liver side effects associated with the use of the drug.

What are the hazards?

Potentially life-threatening or could cause a serious risk to health (Class I).

What should consumers do?

Patients taking Lumiracoxib should stop taking the medicine now and discuss alternative treatments with their doctor.

Supplier
Novartis Pharmaceuticals Australia Pty Ltd
Where the product was sold
Nationally

Responsible regulator

Therapeutic Goods Administration is the responsible regulator for this recall.

Product category